![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Complications, such as retinopathy, nephropathy and neuropathy caused by chronic hyperglycaemia are the greatest problem for patients with diabetes. Although normalisation of hyperglycaemia can prevent these complications, current treatment cannot completely normalise the blood glucose level in patients with Type 2 diabetes. Therefore, better hypoglycaemic agents are desired. Since hyperglycaemia in Type 2 diabetes is induced by insulin resistance, insufficient insulin secretion and increased hepatic glucose production, it is reasonable that investigations into new glucose-lowering agents have been largely dominated by studies on insulin sensitisers, insulin secretagogues and inhibitors of hepatic glucose production. This review summarises the recent patents on drugs of the above three categories.